From the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian cancer is about 1 in 100. Host Dr. Renee Allen is joined by Dr. Evelyn Reynolds to discuss critical updates in ovarian cancer, specifically dispelling the myth about ovarian cancer being a "silent killer." Dr. Reynolds an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine. She is board-certified in General Obstetrics and Gynecology and also Gynecologic Oncology.
From Silent Killer to Treatable Disease: Improved Detection Methods for Ovarian Cancer

Transcript
From Silent Killer to Treatable Disease: Improved Detection Methods for Ovarian Cancer
closeReady to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
From the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian cancer is about 1 in 100. Host Dr. Renee Allen is joined by Dr. Evelyn Reynolds to discuss critical updates in ovarian cancer, specifically dispelling the myth about ovarian cancer being a "silent killer." Dr. Reynolds an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine. She is board-certified in General Obstetrics and Gynecology and also Gynecologic Oncology.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Love Story: Lipid Education for Women’s Heart Health
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Personalizing Care Within the RCC Treatment Paradigm
Navigating Myasthenia Gravis in Adolescents and Young Adults
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?